Skip to content
value.today

Pronutria Biosciences, Inc.

Total raised
$93 M
3 rounds on record
Latest round
$6 M
Sep 2022
First round on record
Jan 2015
Today
Private
No later event on record

Funding rounds

3 counted as startup funding. Open the number of investors for the round's details.

Funding rounds of Pronutria Biosciences, Inc.
MonthRaisedRaiseSizeInvestorsSoldFiling
Sep 2022$6 MNo. 3$2 to $10 million

Pronutria Biosciences, Inc.: Raise no. 3, Sep 2022

Investors in this round

2 investors had bought by the notice of Sep 23, 2022: 2 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round. 8 investors are named for Pronutria Biosciences, Inc. as a whole in other filings: see Investors below.

What the notice says

Amount sold
$6 M of $12 M offered; $6 M still to sell
Smallest investment taken
no minimum stated
What was sold
debt, options or other rights to buy securities
Exemption claimed
  • Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
none
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in Delaware

People named in the notice

  • Margaret Koziel · Executive Officer
  • Paul Fehlner · Executive Officer
  • Robert Crane · Executive Officer
  • Virginia Dean · Executive Officer
  • William Hinshaw · Executive Officer, Director
  • Catherine A. Sohn · Director
  • Cristina M. Rondinone · Director
  • David R. Epstein · Director
  • Gary D. Pisano · Director
  • Martin D. Hendrix · Director
  • Michael D. Rosenblatt · Director
  • Paul D. Sekhri · Director
  • William D. Baird · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

No one: the notice names no broker or finder paid to sell it.

Signed by William Hinshaw, Chief Executive Officer. Source: SEC Form D, newest notice filed Sep 23, 2022. Read the notice at the SEC.

debt, optionsSEC
Feb 2016$43 MNo. 2$10 to $50 million

Pronutria Biosciences, Inc.: Raise no. 2, Feb 2016

Investors in this round

1 investor had bought by the notice of Feb 24, 2017: 1 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round. 8 investors are named for Pronutria Biosciences, Inc. as a whole in other filings: see Investors below.

What the notice says

Amount sold
$43 M (amount offered: indefinite)
Smallest investment taken
no minimum stated
What was sold
equity
Exemption claimed
  • Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
none
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in Delaware

People named in the notice

  • Jeff Barton Moore · Executive Officer
  • Robert Connelly · Executive Officer, Director
  • Charles Cooney · Director
  • Chris Barton Viehbacher · Director
  • David Berry · Director
  • Gary Barton Pisano · Director
  • Gregory Behar · Director
  • John Barton Mendlein · Director
  • Noubar Afeyan · Director
  • Peter Barton Hutt · Director
  • Stephen Hoge · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

No one: the notice names no broker or finder paid to sell it.

Signed by Robert Connelly, President and CFO. Source: SEC Form D and 1 amendment, newest notice filed Feb 24, 2017. Read the notice at the SEC.

equitySEC
Jan 2015$44 MNo. 1$10 to $50 million

Pronutria Biosciences, Inc.: Raise no. 1, Jan 2015

Investors in this round

12 investors had bought by the notice of Feb 24, 2016: 12 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round. 8 investors are named for Pronutria Biosciences, Inc. as a whole in other filings: see Investors below.

What the notice says

Amount sold
$44 M (amount offered: indefinite)
Smallest investment taken
no minimum stated
What was sold
equity
Exemption claimed
  • Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
none
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in Delaware

People named in the notice

  • Garry Barton Menzel · Executive Officer
  • Jeff Barton Moore · Executive Officer
  • Robert Connelly · Executive Officer, Director
  • Charles Cooney · Director
  • Chris Barton Viehbacher · Director
  • David Berry · Director
  • Gary Barton Pisano · Director
  • Gregory Behar · Director
  • John Barton Mendlein · Director
  • Noubar Afeyan · Director
  • Peter Barton Hutt · Director
  • Stephen Hoge · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

No one: the notice names no broker or finder paid to sell it.

Remarks in the notice

  • On the amounts: “The total amount sold in Item 13 and the number of investors in Item 14 includes $1,517,988 from two non U.S. investors.”

Signed by Jeff Moore, Secretary. Source: SEC Form D and 3 amendments, newest notice filed Feb 24, 2016. Read the notice at the SEC.

equitySEC

Source: SEC Form D. Each row is one private sale of securities with the running total of its newest notice. The form does not name the series or the investors; rounds are numbered in the order they were filed. A round's details show what its notice does say: accredited and other investors, the smallest investment taken, the exemption claimed, fees, the people named and the brokers paid to sell it.

How it makes money#

What its filings and its own website say, sentence by sentence, each with its source.

  • Pronutria Biosciences, Inc. chose not to state its revenue in its newest notice of a funding round (Sep 2022).

    SEC Form D · Sep 2022

  • The industry group it chose in its notices: Biotechnology.

    SEC Form D · Sep 2022

That is all the official record says: Pronutria Biosciences, Inc. has not published its revenue in a filing we can read, and no other official source covers it. Revenue figures come from crowdfunding filings (SEC Form C) and from annual reports once a company is listed.

Products and services#

No products or services on record: the address on record now leads to another company's site.

Investors#

8 named in official filings. Open an investor to see everything it has backed.

Investors in Pronutria Biosciences, Inc.
InvestorKindAmountRoundRoleSource
Flagship VentureLabs IV, LLCVenture capitalnot statednot statedHeld Series A, B, C and E preferred stock, 10% owner (Form 3, 2019)SEC Form 3
Flagship Ventures 2007 General Partner LLCVenture capitalnot statednot statedHeld Series A, B, C and E preferred stock, 10% owner (Form 3, 2019)SEC Form 3
Flagship Ventures Fund 2007, L.P.Venture capitalnot statednot statedHeld Series A, B, C and E preferred stock, 10% owner (Form 3, 2019)SEC Form 3
Flagship Ventures Fund IV General Partner LLCVenture capitalnot statednot statedHeld Series A, B, C and E preferred stock, 10% owner (Form 3, 2019)SEC Form 3
Flagship Ventures Fund IV, L.P.Venture capitalnot statednot statedHeld Series A, B, C and E preferred stock, 10% owner (Form 3, 2019)SEC Form 3
Flagship Ventures Fund IV-Rx, L.P.Venture capitalnot statednot statedHeld Series A, B, C and E preferred stock, 10% owner (Form 3, 2019)SEC Form 3
Flagship Ventures Opportunities Fund I General Partner LLCVenture capitalnot statednot statedHeld Series A, B, C and E preferred stock, 10% owner (Form 3, 2019)SEC Form 3
Flagship Ventures Opportunities Fund I, L.P.Venture capitalnot statednot statedHeld Series A, B, C and E preferred stock, 10% owner (Form 3, 2019)SEC Form 3

Source: SEC Form 3 statements, SEC Form N-PORT fund reports, Wikidata, value.today research. Names come from filings that do name holders: the preferred stock each holder had when the company registered its shares (Form 3), private shares in US mutual funds' portfolio reports (N-PORT), and Wikidata. None ties a name to one funding round, so this list is per company, and it is not complete: the 3 rounds above had up to 12 investors.

Executives and directors

As the company named them in its notices. Directors of a funded startup are often partners of its investors.

People named by Pronutria Biosciences, Inc.
NameRoleNamed in
Margaret KozielExecutive officerSep 2022
Paul FehlnerExecutive officerSep 2022
Robert CraneExecutive officerSep 2022
Virginia DeanExecutive officerSep 2022
William HinshawExecutive officerSep 2022
Jeff Barton MooreExecutive officerFeb 2017
Robert ConnellyExecutive officerFeb 2017
Garry Barton MenzelExecutive officerFeb 2016
Catherine A. SohnDirectorSep 2022
Cristina M. RondinoneDirectorSep 2022
David R. EpsteinDirectorSep 2022
Gary D. PisanoDirectorSep 2022
Martin D. HendrixDirectorSep 2022
Michael D. RosenblattDirectorSep 2022
Paul D. SekhriDirectorSep 2022
William D. BairdDirectorSep 2022
William HinshawDirectorSep 2022
Charles CooneyDirectorFeb 2017
Chris Barton ViehbacherDirectorFeb 2017
David BerryDirectorFeb 2017
Gary Barton PisanoDirectorFeb 2017
Gregory BeharDirectorFeb 2017
John Barton MendleinDirectorFeb 2017
Noubar AfeyanDirectorFeb 2017
Peter Barton HuttDirectorFeb 2017
Robert ConnellyDirectorFeb 2017
Stephen HogeDirectorFeb 2017
Glenn Barton NedwinDirectorMay 2015

About

Company in Cambridge, United States.